Buy Liquid ACP-105

ACP-105 Historical Development:

ACP-105 is relatively new to the pharmacological landscape compared to its counterparts in the SARM category. It was first introduced to the scientific community in the early 21st century. Developed by Acadia Pharmaceuticals, ACP-105 was initially synthesized as part of the company’s broader research initiative aimed at finding innovative therapeutics for neurodegenerative disorders. However, researchers soon recognized its potential as a SARM and began to investigate its application in conditions such as osteoporosis and muscle wasting diseases.

ACP-105 Chemical Structure:

Chemically, ACP-105 is known as 1-(2-methylbenzyl)-1H-pyrrolo[3,2-b]quinolin-3-amine. Its molecular structure is characterized by a pyrroloquinoline core, with a methylbenzyl group attached to the pyrrole ring and an amine group attached to the quinoline ring. Unlike traditional anabolic steroids, which are derivatives of the testosterone molecule, ACP-105’s structure is distinct and does not resemble the steroidal scaffold. This unique structure plays a critical role in its selective affinity and activity at androgen receptors.

Properties and Mechanism of Action:

ACP-105 exhibits high affinity and selectivity for the androgen receptor (AR). Like other SARMs, it is designed to confer anabolic effects on muscle and bone tissue while minimizing the undesirable androgenic side effects typically associated with less selective androgens.

The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.